

## CLINICAL RESEARCH

## Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer

JUSTINE E ANDERSON, JENNIFER M HUNT, IAN E SMITH

### Abstract

Scalp cooling with gel packs was used to try to prevent alopecia in 31 patients being treated with doxorubicin (Adriamycin), 29 for advanced breast carcinoma and two for carcinoid tumour. Twenty-eight of the 31 patients tolerated the procedure well, and 22 of these had either no hair loss or only slight loss which remained acceptable and did not require a wig. The main factor limiting success was biochemical impairment of liver function, which occurred in nine patients; of these, six had severe or total alopecia despite scalp cooling. Conversely, the technique was successful in all 19 patients with normal liver function.

Carried out properly, this simple and effective technique greatly diminishes socially unacceptable alopecia associated with doxorubicin, and merits wider use.

### Introduction

The anthracycline antibiotic doxorubicin (Adriamycin) is one of the most active cytotoxic agents currently used in cancer chemotherapy; it has a wide range of antitumour activity and is the most effective single agent in the treatment of advanced breast cancer.<sup>1</sup> Its potential benefits, however, are offset by severe and usually total alopecia, which it causes in nearly all patients.<sup>2</sup> The social and psychological consequences of this are obvious and have undoubtedly restricted its use.

Reports that scalp cooling might reduce the incidence of doxorubicin-induced alopecia<sup>3,4</sup> have been supported by an American study suggesting that this technique prevents hair loss in some patients, especially when doses are less than 50 mg.<sup>5</sup>

We therefore investigated the potential of scalp cooling using a new gel-pack technique in a series of patients receiving doxorubicin.

### Patients and methods

Thirty-one patients were entered into the study; 29 were women with advanced breast carcinoma, and two were men with carcinoid tumour. Their ages ranged from 37 to 73 years (mean 51 years).

The caps used for scalp cooling were made up of 25 × 10 cm polyethylene packs containing a gel which crystallises at -15°C without freezing solid (3M brand); these were moulded together with waterproof tape to form a cap on a wig stand, which was then stored at -20°C until required.

Before scalp cooling began the patient's hair was wetted, gauze and cotton-wool protectors were applied over the ears, and the head was covered with a wet crêpe bandage to reduce the amount of trapped air under the cap and thus improve conduction. The cooled cap was then applied to the bandaged scalp 15 minutes before treatment with doxorubicin and left in place for at least 30 minutes afterwards. The patient was supervised during the procedure, with pillows to support the head. Unless there were specific medical contraindications, patients were treated on an outpatient basis. Patients with advanced breast carcinoma were treated according to our current combination chemotherapy regimen, using 40 mg doxorubicin intravenously on days one and eight of a 28-day cycle, in combination with either 2 mg vincristine or 5 mg vindesine. The two patients with carcinoid tumour were treated with 80 mg doxorubicin intravenously at three-weekly intervals. All received at least two complete cycles of doxorubicin chemotherapy before assessment (total 160 mg). The range of doxorubicin given was 160-520 mg (mean 320 mg).

Patients were assessed by the research nurse before each course of treatment. Response categories to scalp cooling were defined as: (a) no significant hair loss; (b) minor hair loss remaining socially acceptable and not requiring a wig; (c) severe hair loss requiring a wig; and (d) total alopecia.

### Results

tired and ill to persevere. The first few patients complained that the cap felt heavy after 10 minutes or so, which was corrected in all subsequent patients by adequate head support with pillows. Nineteen patients complained of transient light-headedness immediately after the cap was removed; this settled spontaneously within a few minutes.

Twelve of the 28 patients who had a proper trial of scalp cooling experienced no substantial hair loss, though 11 lost pubic and axillary hair. A further 10 experienced only minor hair loss, not requiring a wig or head covering. Thus 22 out of 28 patients had socially acceptable hair protection. The remaining six patients had severe or total alopecia requiring a wig.

Before treatment eight patients had biochemical abnormalities of liver function (raised serum alanine transaminase, alkaline phosphatase, or gammaglutamyl transferase activity) associated with hepatic metastases. A ninth patient developed abnormal liver function immediately after her first course of treatment. Six of the nine had severe or total alopecia despite scalp cooling, including one patient in whom cooling was continued for two hours after treatment with doxorubicin. The other three patients had minor hair loss not requiring a wig.

All 19 patients without biochemical evidence of impaired liver function had successful scalp cooling, either with no appreciable hair loss or with minor loss not requiring a wig.

Four patients had received six months of treatment (total doxorubicin dose 480-520 mg) and a further three five months of treatment (total 400 mg doxorubicin). Five of the seven showed no appreciable hair loss, and two developed minor hair loss in their fifth month of treatment, but not severe enough to require a wig.

Fourteen of the 29 patients with advanced breast carcinoma achieved an objective tumour response (UICC criteria<sup>6</sup>) during treatment. Nine of these patients had already had other chemotherapy; 13 out of 20 previously untreated patients achieved an objective response.

## Discussion

These results confirm that this simple, well-tolerated technique for scalp cooling will prevent or very appreciably diminish doxorubicin-induced alopecia in most patients, with two important provisos. Firstly, we have no experience with doses higher than 40 mg twice-monthly or 80 mg three-weekly. Secondly, the procedure does not appear to be effective for most patients with biochemical evidence of abnormal liver function. This may be predicted on the basis of doxorubicin pharmacokinetics: in patients with normal liver function plasma doxorubicin concentrations fall rapidly after bolus injection during an initial distribution phase with the half life of 1.9 hours; impaired liver function is, however, associated with higher and noticeably more prolonged plasma concentrations, which remain raised for many hours.<sup>7</sup> Thus a 30-minute period of scalp hypothermia after injection would effectively cover the period of highest plasma doxorubicin concentrations in normal patients, whereas cool-

ing for up to two hours after treatment is ineffective in patients with impaired liver function.

We believe that details of the technique, though simple, are important for its success. In particular we think that wetting the hair and applying a wet crêpe bandage before the cooling cap play an important part in the high success rate for this technique by minimising trapped air and associated poor conduction. The relative merits of crushed ice and gel packs may be argued<sup>8</sup>; after an initial trial with crushed ice we preferred to use gel packs because they were simpler to prepare, less uncomfortable to the patients, and associated with less melting water during treatment. The most important problem was the weight of the cap; hence good head support with pillows was essential during treatment. Specially designed gel caps in perhaps two or three different sizes to fit directly on to the scalp would clearly be a useful development.

We conclude that this technique merits wider use in patients being treated with doxorubicin. It seems to us particularly attractive in patients with advanced breast cancer, for whom alopecia represents yet another result of mutilating treatment it may also have an important part to play in encouraging the use of adjuvant doxorubicin for this disease, though the risk of protecting scalp micrometastases would need to be considered. Similar reservations would apply to any form of treatment with curative intent. Finally, further studies are required both with higher doxorubicin dosage and with other alopecia-inducing drugs.

We thank Farmitalia Carlo Erba for their generous research grant to JEA for this project and all the nursing staff at the Royal Marsden Hospital for their willing help.

Requests for reprints should be sent to: Jennifer M Hunt, Department of Nursing Research, Royal Marsden Hospital, London SW 6JJ.

## References

- 1 Tormey DC. Adriamycin in breast cancer. An overview of studies. *Cancer Chemotherapy Reports* 1975;8:319-27.
- 2 Benjamin RS. A practical approach to adriamycin toxicology. *Cancer Chemotherapy Reports* 1975;8:191-4.
- 3 Edelstyn GA, MacDonald M, MacRae KD. Doxorubicin-induced hair loss and possible modification by scalp cooling. *Lancet* 1977;ii:253.
- 4 Timothy AR, Bates TD, Hoy AM. Influence of scalp hypothermia on doxorubicin related alopecia. *Lancet* 1980;i:663.
- 5 Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. *N Engl J Med* 1979;301:1427-9.
- 6 Hayward JL, Rubens RD. Assessment of response to therapy in advanced breast cancer. *Br J Cancer* 1977;35:292-8.
- 7 Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy: efficacy, safety and pharmacologic basis of an intermittent, single, high dosage schedule. *Cancer* 1974;33:19-27.

(Accepted 7 November 1980)